about Jon S. Saxe:
Mr. Saxe has served as a director of over 25 companies and currently is Chairman of the Board of VistaGen (NASDAQ:VTGN) and a board member Durect Corporation (NASDAQ: DRRX). He also serves on the board of the following private companies: Arbor Vita, Arcuo Medical, Cancer Prevention Pharmaceuticals, Epalex, Lumos Pharma and Trellis Bioscience.
Mr. Saxe was President of PDL BioPharma, Inc. (formerly Protein Design Labs, Inc.) (NASDAQ: PDLI) from 1995 to 1999. In 1999-2000 he was Executive-In-Residence at Institutional Venture Partners, a venture capital firm and was principal of Saxe Associates, Inc., consultants to venture capital firms and biotechnology, diagnostic and pharmaceutical companies from 1993 to 1995.
From 1989 to 1993, Mr. Saxe was the President and CEO of Synergen, Inc., a biotechnology company purchased by Amgen. Prior to then, Mr. Saxe was Vice President, Licensing and Corporate Development and Head of Patent Law for Hoffmann-LaRoche Inc., where he worked for 29 years.
Mr. Saxe received a B.S.Ch,E. from Carnegie Mellon University, his J.D. from George Washington University School of Law, his LL.M. from New York University School of Law and a Certificate in Business Administration from Duke University.
Mr. Saxe has served on the Lumos Board since 2012 and was Chairman of the Board from 2012 to 2016.